MGNX
MacroGenics, Inc. NASDAQ Listed Oct 10, 2013$4.58
Pre-mkt
$4.67
+1.97%
Mkt Cap $289.3M
52w Low $1.19
100.0% of range
52w High $4.58
50d MA $3.73
200d MA $2.35
P/E (TTM)
—
EV/EBITDA
—
P/B
5.2x
Debt/Equity
1.9x
ROE
-134.2%
P/FCF
-3.5x
RSI (14)
60.80
ATR (14)
$0.28
Beta
1.10
50d MA
$3.73
200d MA
$2.35
Avg Volume
1.3M
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
9704 Medical Center Drive · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | AMC | -0.57 | -0.58 | -1.8% | 4.16 | -0.7% | +2.2% | +2.4% | +3.9% | -1.3% | -4.9% | — |
| Mar 9, 2026 | AMC | -0.42 | -0.22 | +47.6% | 2.36 | +2.5% | +45.3% | -2.6% | -6.6% | -3.8% | +3.3% | — |
| Nov 12, 2025 | AMC | -0.48 | 0.27 | +156.2% | 1.47 | +12.9% | +8.8% | -6.2% | +0.7% | +2.0% | -7.8% | — |
| Aug 14, 2025 | AMC | -0.59 | -0.57 | +3.4% | 1.62 | -1.2% | -2.5% | -3.8% | -2.0% | +0.0% | -3.4% | — |
| May 13, 2025 | AMC | -0.61 | -0.65 | -6.6% | 1.54 | -1.3% | +0.6% | -0.6% | +2.6% | +0.6% | -1.3% | — |
| Mar 20, 2025 | AMC | -0.23 | -0.25 | -8.7% | 2.10 | -1.0% | -4.8% | -2.0% | -8.7% | -12.8% | -5.1% | — |
| Nov 5, 2024 | AMC | 0.21 | 0.90 | +328.6% | 3.77 | +21.8% | +11.1% | +6.4% | -2.5% | +0.9% | -6.6% | — |
| Aug 6, 2024 | AMC | -0.47 | -0.89 | -89.4% | 3.64 | -3.8% | -7.1% | +2.1% | +2.0% | -4.8% | +5.4% | — |
| May 9, 2024 | AMC | -0.67 | -0.84 | -25.4% | 14.67 | -69.1% | -77.4% | +32.3% | +1.6% | +5.8% | +8.7% | — |
| Mar 7, 2024 | AMC | -0.26 | -0.75 | -188.5% | 20.51 | -5.7% | -15.0% | -2.8% | +3.9% | -5.9% | -3.0% | — |
| Nov 6, 2023 | AMC | -0.11 | -0.52 | -392.9% | 5.44 | +7.9% | +17.1% | +8.2% | -4.9% | -2.3% | -0.5% | — |
| Aug 9, 2023 | AMC | -0.52 | -0.36 | +30.8% | 4.98 | +2.8% | +24.3% | -4.2% | -6.2% | -3.6% | -2.4% | — |
| May 9, 2023 | AMC | 1.07 | -0.61 | -157.0% | 7.18 | -4.3% | +0.4% | -4.7% | -4.2% | -0.9% | -6.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $3.46 | $3.51 | +1.4% | +0.6% | -0.3% | -1.4% | -7.0% | +0.3% |
| Apr 10 | B. Riley Securities | Upgrade | Neutral → Buy | — | $3.44 | $3.70 | +7.6% | +4.7% | -3.6% | +0.6% | +0.9% | -3.1% |
| Mar 10 | Barclays | Maintains | Overweight → Overweight | — | $2.36 | $2.42 | +2.5% | +45.3% | -2.6% | -6.6% | -3.8% | +3.3% |
| Nov 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.66 | $1.65 | -0.6% | -4.8% | -8.2% | -0.7% | -5.6% | +0.7% |
| Aug 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $1.62 | $1.60 | -1.2% | -2.5% | -3.8% | -2.0% | +0.0% | -3.4% |
| May 20 | B. Riley Securities | Maintains | Neutral → Neutral | — | $1.59 | $1.57 | -1.3% | -1.3% | -5.1% | +6.0% | -4.4% | -1.3% |
| May 14 | Barclays | Maintains | Overweight → Overweight | — | $1.54 | $1.52 | -1.3% | +0.6% | -0.6% | +2.6% | +0.6% | -1.3% |
| May 14 | Stifel | Maintains | Hold → Hold | — | $1.54 | $1.52 | -1.3% | +0.6% | -0.6% | +2.6% | +0.6% | -1.3% |
| Mar 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.96 | $1.89 | -3.6% | -8.7% | -12.8% | -5.1% | -14.9% | +0.8% |
| Nov 7 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $4.19 | $4.12 | -1.7% | +6.4% | -2.5% | +0.9% | -6.6% | -8.0% |
| Nov 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.77 | $4.59 | +21.8% | +11.1% | +6.4% | -2.5% | +0.9% | -6.6% |
| Sep 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.37 | $3.37 | +0.0% | -2.1% | +2.7% | -3.2% | -6.7% | -2.0% |
| Aug 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.62 | $3.61 | -0.3% | -0.6% | -7.5% | +4.8% | +2.0% | -3.7% |
| Aug 15 | Citigroup | Maintains | Buy → Buy | — | $3.34 | $3.43 | +2.7% | -2.4% | -0.9% | +9.9% | +2.0% | -0.6% |
| Aug 7 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.64 | $3.50 | -3.8% | -7.1% | +2.1% | +2.0% | -4.8% | +5.4% |
| Aug 1 | BTIG | Downgrade | Buy → Neutral | — | $3.76 | $3.71 | -1.3% | +6.4% | -4.2% | -6.5% | +1.7% | -7.1% |
| Aug 1 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.76 | $3.71 | -1.3% | +6.4% | -4.2% | -6.5% | +1.7% | -7.1% |
| Jul 31 | Barclays | Maintains | Overweight → Overweight | — | $5.25 | $3.68 | -29.9% | -28.4% | +6.4% | -4.2% | -6.5% | +1.7% |
| Jul 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.25 | $3.68 | -29.9% | -28.4% | +6.4% | -4.2% | -6.5% | +1.7% |
| Jul 31 | B. Riley Securities | Downgrade | Buy → Neutral | — | $5.25 | $3.68 | -29.9% | -28.4% | +6.4% | -4.2% | -6.5% | +1.7% |
| Jul 31 | Guggenheim | Downgrade | Buy → Neutral | — | $5.25 | $3.68 | -29.9% | -28.4% | +6.4% | -4.2% | -6.5% | +1.7% |
| Jul 29 | Barclays | Maintains | Overweight → Overweight | — | $5.55 | $5.55 | +0.0% | -1.4% | -4.0% | -28.4% | +6.4% | -4.2% |
| May 24 | BTIG | Maintains | Buy → Buy | — | $4.63 | $4.63 | +0.0% | -1.7% | -4.6% | -4.6% | +2.4% | -3.5% |
| May 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.31 | $3.51 | +6.0% | +32.3% | +1.6% | +5.8% | +8.7% | -14.6% |
| May 10 | TD Cowen | Downgrade | Buy → Hold | — | $14.67 | $4.53 | -69.1% | -77.4% | +32.3% | +1.6% | +5.8% | +8.7% |
| May 10 | Barclays | Maintains | Overweight → Overweight | — | $14.67 | $4.53 | -69.1% | -77.4% | +32.3% | +1.6% | +5.8% | +8.7% |
| May 10 | Stifel | Downgrade | Buy → Hold | — | $14.67 | $4.53 | -69.1% | -77.4% | +32.3% | +1.6% | +5.8% | +8.7% |
| May 10 | BMO Capital | Downgrade | Outperform → Market Perform | — | $14.67 | $4.53 | -69.1% | -77.4% | +32.3% | +1.6% | +5.8% | +8.7% |
| May 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.67 | $4.53 | -69.1% | -77.4% | +32.3% | +1.6% | +5.8% | +8.7% |
| Apr 9 | TD Cowen | Upgrade | Hold → Buy | — | $18.35 | $19.50 | +6.3% | -1.4% | +0.8% | +1.4% | -5.2% | -3.4% |
| Mar 11 | JMP Securities | Maintains | Outperform → Outperform | — | $17.43 | $17.15 | -1.6% | -2.8% | +3.9% | -5.9% | -3.0% | -0.8% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $17.43 | $17.15 | -1.6% | -2.8% | +3.9% | -5.9% | -3.0% | -0.8% |
| Mar 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $17.43 | $17.15 | -1.6% | -2.8% | +3.9% | -5.9% | -3.0% | -0.8% |
| Mar 8 | Barclays | Maintains | Overweight → Overweight | — | $20.51 | $19.34 | -5.7% | -15.0% | -2.8% | +3.9% | -5.9% | -3.0% |
| Mar 8 | Stifel | Maintains | Buy → Buy | — | $20.51 | $19.34 | -5.7% | -15.0% | -2.8% | +3.9% | -5.9% | -3.0% |
| Mar 8 | BMO Capital | Maintains | Outperform → Outperform | — | $20.51 | $19.34 | -5.7% | -15.0% | -2.8% | +3.9% | -5.9% | -3.0% |
| Mar 4 | BTIG | Maintains | Buy → Buy | — | $19.06 | $19.78 | +3.8% | +8.7% | -0.4% | +4.0% | -4.5% | -15.0% |
| Feb 29 | Barclays | Maintains | Overweight → Overweight | — | $17.19 | $17.84 | +3.8% | +4.4% | +6.2% | +8.7% | -0.4% | +4.0% |
| Feb 14 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $17.35 | $16.62 | -4.2% | -1.3% | +1.6% | -0.7% | -0.6% | -0.8% |
| Jan 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.01 | $12.55 | +4.5% | +0.0% | +6.6% | +3.3% | +3.2% | +2.6% |
| Dec 20 | Citigroup | Upgrade | Neutral → Buy | — | $9.23 | $10.08 | +9.2% | +6.5% | +1.7% | -1.3% | +2.4% | -1.5% |
| Nov 27 | Stifel | Maintains | Buy → Buy | — | $7.50 | $7.40 | -1.3% | +2.0% | -2.1% | +0.4% | +9.2% | +2.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.40 | $6.47 | +1.1% | -0.5% | +10.5% | +3.3% | -2.5% | +7.1% |
| Nov 7 | Guggenheim | Upgrade | Neutral → Buy | — | $5.44 | $5.87 | +7.9% | +17.1% | +8.2% | -4.9% | -2.3% | -0.5% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $5.12 | +2.8% | +24.3% | -4.2% | -6.2% | -3.6% | -2.4% |
| May 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.21 | $7.28 | +1.0% | -4.7% | -4.2% | -0.9% | -6.9% | +0.5% |
| Mar 21 | BTIG | Maintains | Buy → Buy | — | $6.69 | $6.87 | +2.7% | +6.4% | -5.8% | +3.6% | -3.9% | +1.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $6.80 | +2.3% | +0.6% | +6.4% | -5.8% | +3.6% | -3.9% |
| Mar 17 | Guggenheim | Downgrade | Buy → Neutral | — | $6.99 | $6.35 | -9.2% | -4.9% | +0.6% | +6.4% | -5.8% | +3.6% |
| Jan 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.39 | $5.25 | -2.6% | -2.6% | +10.3% | +1.4% | +6.1% | -0.2% |
No insider trades available.
8-K · 1.01
!! High
MacroGenics, Inc. -- 8-K 1.01: Supply Agreement
MacroGenics acquired Bora Pharmaceuticals' assets for $122.5 million, potentially expanding its oncology pipeline and diversifying its therapeutic portfolio through this strategic purchase.
May 12
8-K · 1.01
!! High
MacroGenics, Inc. -- 8-K 1.01: License Agreement
MacroGenics licensed technology to Sage Therapeutics for $60 million upfront, providing near-term revenue while validating its platform and potentially generating future royalties.
May 4
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA's removal of the clinical hold on Magenta's lorigerlimab Phase 2 study de-risks development and allows trial resumption, potentially accelerating a promising dual-target immunotherapy toward commercialization.
Apr 8
8-K
MacroGenics, Inc. -- 8-K Filing
MacroGenics reported $189.9 million in cash with runway extending to late 2027, while advancing four programs including novel ADCs with Phase 1 readouts expected through late 2026.
Mar 9
8-K · 8.01
!! High
MacroGenics, Inc. -- 8-K 8.01: Material Event / Announcement
MacroGenics' CEO Siegel resigned for personal reasons, signaling potential leadership transition uncertainty for investors in this clinical-stage biopharmaceutical company.
Mar 2
8-K · 8.01
!! High
MacroGenics, Inc. -- 8-K 8.01: Material Event / Announcement
MacroGenics faces a setback as the FDA placed a partial clinical hold on its lorigerlimab Phase 2 gynecologic cancer study, potentially delaying development timelines and affecting the company's pipeline progress.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Renaissance Technologies Llc | 2,963,559 | $9M | Added | Mar 2026 |
| 2 | Millennium Management | 2,794,357 | $8M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,653,853 | $8M | New | Mar 2026 |
| 4 | Acadian Asset Management Llc | 2,544,000 | $7M | Added | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 2,527,829 | $7M | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 2,401,814 | $7M | Added | Mar 2026 |
| 7 | Marshall Wace, Llp | 2,025,526 | $6M | Added | Mar 2026 |
| 8 | Wasatch Advisors Lp | 1,559,701 | $5M | Reduced | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 1,208,775 | $3M | New | Mar 2026 |
| 10 | D.e. Shaw & Co | 1,058,424 | $3M | Added | Mar 2026 |
| 11 | Citadel Advisors Llc | 782,618 | $2M | Reduced | Mar 2026 |
| 12 | Jane Street Group, Llc | 1,254,923 | $2M | Added | Dec 2025 |
| 13 | Walleye Capital Llc | 670,530 | $2M | Added | Mar 2026 |
| 14 | Connor, Clark & Lunn Investment Management Ltd. | 818,820 | $1M | Added | Dec 2025 |
| 15 | Susquehanna International Group, Llp | 452,227 | $1M | Added | Mar 2026 |
| 16 | Ubs Group Ag | 296,086 | $856K | Added | Mar 2026 |
| 17 | Pinnacle Associates Ltd | 279,121 | $807K | Reduced | Mar 2026 |
| 18 | Amundi | 214,278 | $619K | New | Mar 2026 |
| 19 | Point72 Asset Management | 208,583 | $603K | Reduced | Mar 2026 |
| 20 | Qube Research & Technologies Ltd | 187,464 | $542K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$289.3M
Enterprise Value
$169.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.13x
P/B
5.20x
P/S
1.84x
P/FCF
-3.49x
EV/EBITDA
—
Shares Out
63.2M
Financials (TTM)
Revenue
$157.1M
Net Income
-$70.4M
EBITDA
-$50.6M
Free Cash Flow
-$83.0M
Op Cash Flow
-$81.0M
EPS Basic
$-1.18
EPS Diluted
$-1.10
EPS Forward
$-1.47
Gross Margin
69.9%
Op Margin
-40.5%
Net Margin
-44.8%
Balance Sheet
Total Assets
$256.8M
Total Liab.
$201.3M
Total Equity
$55.6M
Cash
$189.9M
LT Debt
$70.0M
Book Value/Sh
$0.88
Debt/Equity
1.92x
Current Ratio
5.10
Quick Ratio
4.92
Returns & Growth
ROE
-134.2%
ROA
-29.0%
ROIC
-33.0%
Rev Growth YoY
+0.8%
EPS Growth YoY
-10.3%
Price Returns
2W
+0.0%
1M
+35.1%
3M
+109.0%
6M
+171.9%
12M
+205.9%
Technicals
52W High
$4.58
52W Low
$1.19
50d MA
$3.73
200d MA
$2.35
RSI (14)
60.80
ATR (14)
$0.28
Beta
1.10
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 26, 2026 12:07pm
· Source: financialmodelingprep.com